12/3
06:10 pm
meso
Mesoblast Participation at Piper Sandler Conference
Low
Report
Mesoblast Participation at Piper Sandler Conference
11/24
08:16 pm
meso
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue [Yahoo! Finance]
Low
Report
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue [Yahoo! Finance]
11/24
06:39 pm
meso
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Low
Report
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
11/20
07:08 pm
meso
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids [Yahoo! Finance]
Medium
Report
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids [Yahoo! Finance]
11/20
06:32 pm
meso
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
Medium
Report
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
11/17
02:13 am
meso
James M. O'Brien Appointed Chief Financial Officer at Mesoblast [Yahoo! Finance]
Medium
Report
James M. O'Brien Appointed Chief Financial Officer at Mesoblast [Yahoo! Finance]
11/17
01:52 am
meso
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
Medium
Report
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
11/4
06:54 pm
meso
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation [Yahoo! Finance]
Low
Report
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation [Yahoo! Finance]
11/4
06:40 pm
meso
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Low
Report
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
10/25
12:09 pm
meso
Mesoblast (NASDAQ:MESO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mesoblast (NASDAQ:MESO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/19
07:48 pm
meso
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
Medium
Report
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
10/17
10:29 pm
meso
Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement [Yahoo! Finance]
Medium
Report
Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement [Yahoo! Finance]
10/7
12:35 am
meso
Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales [Seeking Alpha]
Low
Report
Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales [Seeking Alpha]
10/6
07:24 pm
meso
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
Medium
Report
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
10/2
09:04 pm
meso
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
Medium
Report
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
10/1
02:07 pm
meso
Mesoblast Limited (MESO)'s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs [Yahoo! Finance]
Low
Report
Mesoblast Limited (MESO)'s Ryoncil® Gains U.S.-Origin Status, Avoids Import Tariffs [Yahoo! Finance]
9/26
01:49 am
meso
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
Low
Report
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
9/14
09:18 pm
meso
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Low
Report
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences